earningsconfidence high
Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel
ARVINAS, INC.
2026-Q1 EPS
reported -$0.90
vs consensus -$0.94
▲ beat
(+4.0%)
- FDA approved VEPPANU (vepdegestrant) for ESR1m, ER+/HER2- advanced breast cancer — first PROTAC therapy approved.
- Entered license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU; closing subject to HSR approval.
- Cash and equivalents $614.9M at Mar 31, 2026 (Dec 31, 2025: $685.4M); cash runway into 2H 2028.
- Randy Teel appointed President, CEO, and Director; Briggs Morrison elected Chair of the Board.
- ARV-102 Phase 1: >50% LRRK2 degradation in CSF; ARV-806 KRAS G12D dose escalation complete; ARV-027 Phase 1 initiated.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.